TY - JOUR
T1 - Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission
T2 - a Danish population-based cohort study
AU - Lund, Lars Christian
AU - Hallas, Jesper
AU - Nielsen, Henrik
AU - Koch, Anders
AU - Mogensen, Stine Hasling
AU - Brun, Nikolai Constantin
AU - Christiansen, Christian Fynbo
AU - Thomsen, Reimar Wernich
AU - Pottegard, Anton
PY - 2021
Y1 - 2021
N2 - Background Individuals admitted to hospital for COVID-19 might have persisting symptoms (so-called long COVID) and delayed complications after discharge. However, little is known regarding the risk for those not admitted to hospital. We therefore examined prescription drug and health-care use after SARS-CoV-2 infection not requiring hospital admission. Methods This was a population-based cohort study using the Danish prescription, patient, and health insurance registries. All individuals with a positive or negative RT-PCR test for SARS-CoV-2 in Denmark between Feb 27 and May 31, 2020, were eligible for inclusion. Outcomes of interest were delayed acute complications, chronic disease, hospital visits due to persisting symptoms, and prescription drug use. We used data from non-hospitalised SARS-CoV-2-positive and matched SARS-CoV-2-negative individuals from 2 weeks to 6 months after a SARS-CoV-2 test to obtain propensity score-weighted risk differences (RDs) and risk ratios (RRs) for initiation of 14 drug groups and 27 hospital diagnoses indicative of potential post-acute effects. We also calculated prior event rate ratio-adjusted rate ratios of overall health-care use. This study is registered in the EU Electronic Register of Post-Authorisation Studies (EUPAS37658). Findings 10 498 eligible individuals tested positive for SARS-CoV-2 in Denmark from Feb 27 to May 31, 2020, of whom 8983 (85middot6%) were alive and not admitted to hospital 2 weeks after their positive test. The matched SARS-CoV-2negative reference population not admitted to hospital consisted of 80 894 individuals. Compared with SARS-CoV-2negative individuals, SARS-CoV-2-positive individuals were not at an increased risk of initiating new drugs (RD
AB - Background Individuals admitted to hospital for COVID-19 might have persisting symptoms (so-called long COVID) and delayed complications after discharge. However, little is known regarding the risk for those not admitted to hospital. We therefore examined prescription drug and health-care use after SARS-CoV-2 infection not requiring hospital admission. Methods This was a population-based cohort study using the Danish prescription, patient, and health insurance registries. All individuals with a positive or negative RT-PCR test for SARS-CoV-2 in Denmark between Feb 27 and May 31, 2020, were eligible for inclusion. Outcomes of interest were delayed acute complications, chronic disease, hospital visits due to persisting symptoms, and prescription drug use. We used data from non-hospitalised SARS-CoV-2-positive and matched SARS-CoV-2-negative individuals from 2 weeks to 6 months after a SARS-CoV-2 test to obtain propensity score-weighted risk differences (RDs) and risk ratios (RRs) for initiation of 14 drug groups and 27 hospital diagnoses indicative of potential post-acute effects. We also calculated prior event rate ratio-adjusted rate ratios of overall health-care use. This study is registered in the EU Electronic Register of Post-Authorisation Studies (EUPAS37658). Findings 10 498 eligible individuals tested positive for SARS-CoV-2 in Denmark from Feb 27 to May 31, 2020, of whom 8983 (85middot6%) were alive and not admitted to hospital 2 weeks after their positive test. The matched SARS-CoV-2negative reference population not admitted to hospital consisted of 80 894 individuals. Compared with SARS-CoV-2negative individuals, SARS-CoV-2-positive individuals were not at an increased risk of initiating new drugs (RD
KW - EXISTING DATA SOURCES
KW - CLINICAL EPIDEMIOLOGY
KW - COVID-19
U2 - 10.1016/S1473-3099(21)00211-5
DO - 10.1016/S1473-3099(21)00211-5
M3 - Journal article
SN - 1473-3099
VL - 21
SP - 1373
EP - 1382
JO - Lancet Infectious Diseases
JF - Lancet Infectious Diseases
IS - 10
ER -